The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2022 | CheckMate 648: Novel treatment for patients with advanced esophageal squamous cell carcinoma
Hisato Kawakami, MD, PhD, Kindai University, Osaka, Japan, talks on the Phase III CheckMate 648 (NCT03143153) trial, in which the efficacy of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin was compared to fluorouracil plus cisplatin only in patients with unresectable advanced, recurrent or metastatic previously-untreated esophageal squamous cell carcinoma. Dr Kawakami comments on the several factors which were associated with a delayed therapeutic onset of treatment with nivolumab plus ipilimumab, including age and alcohol use, and the implications of this. Moreover, the Glasgow Prognostic Score (GPS) and its association with the efficacy of nivolumab plus ipilimumab is discussed. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.
Disclosures
Honoraria（lecture fee) from: BMS K.K., ONO Pharmaceutical Co., LTD., Taiho Pharmaceutical Co., Ltd., and Daiichi Sankyo, Co., Ltd.
Grant/Research funding from: BMS K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Kobayashi Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co., Ltd., and Daiichi Sankyo, Co., Ltd.
